OTC drug private label giant Perrigo Co. PLC will change its focus from health care to "self care" and compete outside its core sector to solve its revenue problems, says recently appointed CEO Murray Kessler.
Perrigo Pivots To 'Self Care' For 'Massive Opportunity' Beyond OTC Drugs
Providing self-care products "opens this organization up to massive opportunity" which Perrigo will identify in early 2019, says new CEO Murray Kessler. It remains committed to selling or spinning off its Rx unit, though it's "just a few FDA approvals away from significantly" growing, he says as firm reports $68m net loss in its latest quarter.